Fluoride

Fluoride

SCHEMBL633913

CCN(CC)CC.F.[F-].[H+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL3926229 1.00 ALDH1A1 (0.31)
Fluoride SCHEMBL1062136 1.00 ALDH1A1 (0.31)
Fluoride SCHEMBL28235374 0.95
Fluoride Ion SCHEMBL963997 0.95
Fluoride Ion SCHEMBL131861 0.95 ALDH1A1 (0.33)
Fluoride SCHEMBL1263596 0.95
Fluoride SCHEMBL6229645 0.95
SCHEMBL1334882 0.91
Fluoride SCHEMBL13581787 0.91 ALDH1A1 (0.36)
Fluoride SCHEMBL99441 0.91

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2018-10-16 US disclosed
EP-1028124-B2 Improved deprotection method for the synthesis of oligomeric compounds ISIS PHARMACEUTICALS INC (US) 2016-01-27 EP disclosed
US-9051501-B2 Curable composition and catalyst composition KANEKA CORPORATION (JP) 2015-06-09 US disclosed
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION GILEAD SCIENCES, INC. (US) 2014-02-27 US disclosed
EP-2251015-B1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2013-02-20 EP disclosed
EP-2088173-B1 CURABLE COMPOSITION AND CATALYST COMPOSITION KANEKA CORP (JP) 2012-02-22 EP disclosed
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PHARMASSET, INC. 2011-11-03 US disclosed
EP-2302000-A1 Curable composition and catalyst composition KANEKA CORPORATION (JP) 2011-03-30 EP disclosed
EP-1411954-B1 MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION PHARMASSET INC (US) 2010-12-15 EP disclosed
EP-2251015-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation Pharmasset, Inc. (US) 2010-11-17 EP disclosed
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation PHARMASSET, INC. 2003-05-08 US disclosed
US-20030088088-A1 Process for the synthesis of oligomeric compounds IONIS PHARMACEUTICALS, INC. 2003-05-08 US disclosed
US-6465628-B1 METHOD OF SYNTHESIS WITH DEPROTECTION OF OLIGOMERS ISIS PHARMACEUTICALS, INC. 2002-10-15 US disclosed
WO-2002078619-A2 ALKYNYLATED SINGLE-STRAND OLIGONUCLEOTIDE AND USES THEREOF UNIVERSITY OF ROCHESTER (US) 2002-10-10 WO disclosed
WO-2002072864-A2 REAGENTS FOR OLIGONUCLEOTIDE CLEAVAGE AND DEPROTECTION APPLERA CORPORATION (US) 2002-09-19 WO disclosed
EP-1232166-A2 SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES Pharmasset Limited (US) 2002-08-21 EP disclosed
WO-2002048165-A2 ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS PHARMASSET LTD. (BB) 2002-06-20 WO disclosed
WO-2002032920-A2 MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION PHARMASSET LIMITED (BB) 2002-04-25 WO disclosed
WO-2001034618-A2 SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES PHARMASSET LIMITED (US) 2001-05-17 WO disclosed
EP-1028124-A2 Improved process for the synthesis of oligomeric compounds ISIS PHARMACEUTICALS, INC. (US) 2000-08-16 EP disclosed